{"url":"https://lda.senate.gov/api/v1/filings/d723d02a-cdb1-4315-a09d-e07f9db5e519/","filing_uuid":"d723d02a-cdb1-4315-a09d-e07f9db5e519","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/d723d02a-cdb1-4315-a09d-e07f9db5e519/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"John E. Pence","dt_posted":"2026-04-20T09:16:56-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1455 Pennsylvania Avenue, NW","registrant_address_2":"Suite 400","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":401109481,"url":"https://lda.senate.gov/api/v1/registrants/401109481/","house_registrant_id":76976,"name":"FRONTLINE GOVERNMENT RELATIONS","description":null,"address_1":"1455 Pennsylvania Avenue, NW","address_2":"Suite 400","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JOHN PENCE","contact_telephone":"+1 202-878-9220","dt_updated":"2026-07-16T10:17:06.944922-04:00"},"client":{"id":65940,"url":"https://lda.senate.gov/api/v1/clients/65940/","client_id":65940,"name":"EMPOWER PHARMACY","general_description":"Compounding pharmacy","client_government_entity":null,"client_self_select":false,"state":"TX","state_display":"Texas","country":"US","country_display":"United States of America","ppb_state":"TX","ppb_state_display":"Texas","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-04-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocated for clarity and fairness in the regulation of pharmaceutical compounding by the Food and Drug Administration (FDA), including issues related to compliance with Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":149297,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"PENCE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150797,"prefix":null,"prefix_display":null,"first_name":"ELLIOTT","nickname":null,"middle_name":null,"last_name":"ECHOLS","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MAN","general_issue_code_display":"Manufacturing","description":"Advocated for regulatory clarity and proportional enforcement in the oversight of outsourcing facility manufacturing under Section 503B of the Federal Food, Drug, and Cosmetic Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":149297,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"PENCE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}